文献速递脑血管病

DEFUSE 3 试验:血管内治疗改善缺血性卒中患者生理、社交与认知领域生活质量

Quality of Life in Physical, Social, and Cognitive Domains Improves With Endovascular Therapy in the DEFUSE 3 Trial.
PubMed 文献 · Stroke · 2021-02-18

DEFUSE 3 试验二次分析纳入 182 例发病 6–16 小时的前循环缺血性卒中患者,随机接受血管内取栓联合标准药物治疗或单纯标准药物治疗。90 天时血管内治疗组在 mobility、社会参与、认知功能和抑郁各领域的生活质量评分均更优(P<0.01),而 modified Rankin Scale 对认知和抑郁差异的捕捉能力有限。

要点

  • 晚时间窗(6–16 小时)血管内治疗在多个生活质量领域优于单纯药物治疗。
  • modified Rankin Scale 对认知和抑郁的捕捉能力低,应使用专用生活质量工具评估。
  • 较低基线 NIHSS、较年轻年龄和男性与更好的生活质量独立相关。

核心结论

  • 发病 6–16 小时接受血管内治疗的患者,90 天生活质量优于单纯药物治疗,包括 mobility 更好、社会参与更多、认知更优和抑郁更少。
  • modified Rankin Scale 未能捕捉认知和抑郁方面的患者结局,应使用专用生活质量工具评估。

研究设计与样本

  • DEFUSE 3 随机临床试验的二次分析,纳入 182 例发病 6–16 小时的前循环急性缺血性卒中患者。
  • 患者随机接受血管内取栓联合标准药物治疗或单纯标准药物治疗,随访至卒中后 90 天。
  • 90 天生活质量采用 QoL in Neurological Disorders 测量工具评估。

主要发现

  • 90 天时 146 例存活受试者中,136 例(95%)填写了 QoL in Neurological Disorders 简表。
  • 血管内治疗组在 mobility、社会参与、认知功能和抑郁各领域的生活质量评分均更优(P<0.01 for all)。
  • 除血管内治疗外,与更好生活质量独立相关的变量包括较低基线 National Institutes of Health Stroke Scale、较年轻年龄和男性。
  • modified Rankin Scale 评分对 mobility 变异的解释比例高(Rs2=0.82),对社会参与为中等(Rs2=0.62),对认知(Rs2=0.31)和抑郁(Rs2=0.19)为低。

临床怎么用

  • 对晚时间窗(6–16 小时)前循环缺血性卒中患者,血管内治疗可改善多领域生活质量。
  • 评估此类患者结局时,除 modified Rankin Scale 外应使用专用生活质量工具评估认知和抑郁。

局限性

  • 本文为 DEFUSE 3 试验的二次分析,生活质量并非主要终点。
  • 90 天时仅 136 例(95% 存活者)填写了生活质量简表,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: The DEFUSE 3 (Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3) randomized clinical trial demonstrated the efficacy of endovascular therapy in treating ischemic stroke 6 to 16 hours after onset, resulting in better functional outcomes than standard medical therapy alone. The objective of this secondary analysis is to analyze the effect of late-window endovascular treatment of ischemic stroke on quality of life (QoL) outcomes. METHODS: Patients (n=182) who presented between 6 and 16 hours after they were last known to be well with acute anterior circulation ischemic stroke were randomized to endovascular thrombectomy plus standard medical therapy or standard medical therapy alone and followed-up through 90 days poststroke. QoL at day 90 was assessed with the QoL in Neurological Disorders measurement tool. RESULTS: Of the 146 subjects alive at day 90, 136 (95%) filled out QoL in Neurological Disorders short forms. Patients treated with endovascular therapy had better QoL scores in each domain: mobility, social participation, cognitive function, and depression (P<0.01 for all). Variables other than endovascular therapy that were independently associated with better QoL included lower baseline National Institutes of Health Stroke Scale, younger age, and male sex. The degree to which the modified Rankin Scale captures differences in QoL between patients varied by domain; the modified Rankin Scale score accounted for a high proportion of the variability in mobility (Rs2=0.82), a moderate proportion in social participation (Rs2=0.62), and a low proportion in cognition (Rs2=0.31) and depression (Rs2=0.19). CONCLUSIONS: Patients treated with endovascular therapy 6 to 16 hours after stroke have better QoL than patients treated with medical therapy alone, including better mobility, more social participation, superior cognition, and less depression. The modified Rankin Scale fails to capture patients' outcomes in cognition and depression, which should therefore be assessed with dedicated QoL tools. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02586415.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Polding LC, Tate WJ, Mlynash M, et al. Quality of Life in Physical, Social, and Cognitive Domains Improves With Endovascular Therapy in the DEFUSE 3 Trial. Stroke. 2021. PMID: 33596675. doi:10.1161/STROKEAHA.120.031490

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。